Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label AFQ056 extension study in Parkinson's disease with levodopa-induced dyskinesia
2010-019418-25Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavoglurant in Parkinson's disease (PD) and levodopa-induced dyskinesia (LID), sponsored by Novartis. Primary endpoints: Safety and tolerability of AFQ056, Vital signs, laboratory assessments, and ECG changes and 4 more. Started Jul 2010; status: terminated.
02
Drugs
mavoglurant
03
Conditions
Parkinson's disease (PD)levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on 2010-019418-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019418-25.